These findings provided the basis for their translation to a Phase Ib/IIa trial of combining GO-203 with decitabine for the treatment patients with relapsed/refractory AML.
These findings provided the basis for their translation to a Phase Ib/IIa trial of combining GO-203 with decitabine for the treatment patients with relapsed/refractory AML.
|
Company |
|